{"product_id":"bioactive-based-nanotherapeutics-hardback-9781394287314","title":"Bioactive-Based Nanotherapeutics (Hardback) 9781394287314","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eBioactive-Based Nanotherapeutics\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eRakesh K. Sindhu (Edited by), Sumitra Singh (Edited by), Evren Algin Yapar (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781394287314, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 24 July 2025\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e768 pages\u003cbr\u003e28 x 19 x 2.6 cm, 0.666 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003cb\u003eThe book provides essential insights into the revolutionary potential of nanotechnology in medicine, exploring innovative approaches that harness natural materials for targeted and effective disease management.\u003c\/b\u003e \u003c\/p\u003e\n\u003cp\u003eNanotechnology has emerged as an innovative field with the potential to transform various sectors, including medicine and allied health sciences. Bioactive nanotherapeutics, a specific area within nanotherapeutics, utilizes natural materials or biomimetic designs to offer distinct advantages such as targeted drug delivery, biocompatibility, and improved therapeutic efficacy. These bioactive-based nanotherapeutics are used in the treatment and management of various diseases. \u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eBioactive-Based Nanotherapeutics\u003c\/i\u003e explores this rapidly growing field of therapeutics. It presents a broad overview of the fundamentals of bioactive nanomaterials, their design strategies, and their therapeutic applications. Leading experts from different disciplines have contributed chapters that explore a diverse range of topics, including the basics of bioactive nanotherapeutics, isolation methods of different bioactive compounds, and formulation developments. This volume addresses the importance of nanotechnology for the treatment and management of different diseases, including nasal, gastrointestinal, rectal, and transdermal diseases. \u003c\/p\u003e\n\u003cp\u003eReaders will find the book: \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProvides scientific research and evidence that supports the effectiveness of bioactive-based nanocarriers in treating diseases;\u003c\/li\u003e \u003cli\u003eExplores actionable steps and real-life scenarios to illustrate the practical benefits;\u003c\/li\u003e \u003cli\u003eProvides a comprehensive guide that explains the holistic approach, explaining health-related applications of bioactive-based nanoformulations.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003e\u003cb\u003eAudience\u003c\/b\u003e \u003c\/p\u003e\n\u003cp\u003ePharmacists, biologists, chemists, doctors, academics, and industry professionals interested in holistic and bioactive-based methods for disease treatment.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003ePreface xxxi\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Basics of Nano-Bioactive Compounds and Their Therapeutic Potential 1\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJannat ul Firdaus, Sumitra Singh and Rakesh K. Sindhu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 2\u003c\/p\u003e \u003cp\u003e1.2 Therapeutic Potential of Bioactive Compounds 3\u003c\/p\u003e \u003cp\u003e1.3 Extraction Techniques for Obtaining Bioactive Compound 8\u003c\/p\u003e \u003cp\u003e1.4 Novel Delivery Approach for Bioactive Compounds 9\u003c\/p\u003e \u003cp\u003e1.5 Electrospinning 11\u003c\/p\u003e \u003cp\u003e1.6 Micro- and Nanoencapsulation of Bioactive Compounds 11\u003c\/p\u003e \u003cp\u003e1.7 Polymeric Nanoparticles (NPs) 12\u003c\/p\u003e \u003cp\u003e1.8 Solid Lipid Nanoparticles 12\u003c\/p\u003e \u003cp\u003e1.9 Nanoemulsions 12\u003c\/p\u003e \u003cp\u003e1.10 Nanocrystals 13\u003c\/p\u003e \u003cp\u003e1.11 Phytosomes 13\u003c\/p\u003e \u003cp\u003e1.12 Therapeutic Potential of Nano-Bioactive Compounds 14\u003c\/p\u003e \u003cp\u003e1.13 Conclusion 17\u003c\/p\u003e \u003cp\u003eReferences 18\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Recent Techniques for Isolation of Bioactive Components from Plants 27\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eOmonike O. Ogbole, Oluwagbenga V. Kayode, Feranmi J. Adelowokan and Oluwatoyin A. Odeku\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 28\u003c\/p\u003e \u003cp\u003e2.2 Extraction Methods 30\u003c\/p\u003e \u003cp\u003e2.3 Recent Chromatographic Methods 35\u003c\/p\u003e \u003cp\u003e2.4 Applications of Two-Dimensional Chromatographic Approaches 40\u003c\/p\u003e \u003cp\u003e2.5 Hyphenated Techniques 40\u003c\/p\u003e \u003cp\u003e2.6 Conclusion 43\u003c\/p\u003e \u003cp\u003eReferences 43\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Bioactive-Based Nanocarriers for Inflammatory Diseases 55\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJasdev Singh Tuteja, Supriya Shidhaye, Anamika Singh and Tamanna Narsinghani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Inflammation and Diseases 56\u003c\/p\u003e \u003cp\u003e3.2 Nanocarriers as Drug Delivery System 58\u003c\/p\u003e \u003cp\u003e3.3 Nanocarriers and Inflammation 59\u003c\/p\u003e \u003cp\u003e3.4 Inflammation in Central Nervous System 60\u003c\/p\u003e \u003cp\u003e3.5 Ophthalmological Inflammation 63\u003c\/p\u003e \u003cp\u003e3.6 Cardiovascular Inflammation 65\u003c\/p\u003e \u003cp\u003e3.7 Respiratory Inflammation 68\u003c\/p\u003e \u003cp\u003e3.8 Inflammation in Gastric System 73\u003c\/p\u003e \u003cp\u003e3.9 Excretory System Inflammation 77\u003c\/p\u003e \u003cp\u003e3.10 Inflammation of the Reproductive System 81\u003c\/p\u003e \u003cp\u003e3.11 Inflammation Associated with Dermatology 85\u003c\/p\u003e \u003cp\u003e3.12 Muscular Inflammation 89\u003c\/p\u003e \u003cp\u003e3.13 Skeletal Inflammation 92\u003c\/p\u003e \u003cp\u003e3.14 Applications of Nanocarriers in Inflammation 96\u003c\/p\u003e \u003cp\u003e3.15 Conclusion 101\u003c\/p\u003e \u003cp\u003eReferences 102\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Bioactive-Based Nanocarriers for Dermal Diseases 115\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eNitika Garg, Sanchit Dhankhar, Samrat Chauhan and Suresh Beniwal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 116\u003c\/p\u003e \u003cp\u003e4.2 Skin Anatomy and Physiology: Implications for Drug Delivery 117\u003c\/p\u003e \u003cp\u003e4.3 Barrier Functions of the Skin 119\u003c\/p\u003e \u003cp\u003e4.4 Transdermal Permeation Challenges 119\u003c\/p\u003e \u003cp\u003e4.5 Factors Influencing Dermal Drug Penetration 120\u003c\/p\u003e \u003cp\u003e4.6 Role of Nanocarriers in Enhancing Drug Penetration 122\u003c\/p\u003e \u003cp\u003e4.7 Types of Bioactive-Based Nanocarriers 129\u003c\/p\u003e \u003cp\u003e4.8 Design Principles and Fabrication Techniques 129\u003c\/p\u003e \u003cp\u003e4.9 Characterization of Bioactive-Based Nanocarriers 130\u003c\/p\u003e \u003cp\u003e4.10 Applications in Diverse Dermal Diseases 132\u003c\/p\u003e \u003cp\u003e4.11 Preclinical Studies: In Vivo and In Vitro 140\u003c\/p\u003e \u003cp\u003e4.12 Challenges and Future Directions 142\u003c\/p\u003e \u003cp\u003e4.13 Conclusion 143\u003c\/p\u003e \u003cp\u003eReferences 144\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Nano-Based Nasal Delivery of Biomacromolecules: A Myriad of Opportunities 151\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGenada Sinani, Sevgi Güngör, Yıldız Özsoy and Erdal Cevher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Biomacromolecules 152\u003c\/p\u003e \u003cp\u003e5.2 Characteristics of Biomacromolecules and Delivery Challenges 153\u003c\/p\u003e \u003cp\u003e5.3 Opportunities of Nasal Route 156\u003c\/p\u003e \u003cp\u003e5.4 Main Factors in Nasal Cavity Affecting Delivery of Biomacromolecules 157\u003c\/p\u003e \u003cp\u003e5.5 Nano-Based Delivery Systems as an Efficient Strategy to Improve Intranasal Administration of Biomacromolecules 160\u003c\/p\u003e \u003cp\u003e5.6 Proof of Concept: Biomacromolecules Administered by Intranasal Nano-Based Delivery Systems 167\u003c\/p\u003e \u003cp\u003e5.7 Safety Considerations 184\u003c\/p\u003e \u003cp\u003e5.8 Conclusion 185\u003c\/p\u003e \u003cp\u003eReferences 187\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Bioactive-Based Nanocarriers for Ocular Application 199\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eIshita Bhardwaj, Atifa Haseeb Ansari, Swayam Prabha Rai, Durgesh Singh and Sippy Singh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 200\u003c\/p\u003e \u003cp\u003e6.2 Barriers and Route of Ocular Drug Delivery 200\u003c\/p\u003e \u003cp\u003e6.3 Nanoparticles in Ocular Diseases Therapy 201\u003c\/p\u003e \u003cp\u003e6.4 Organic Nanocarriers 202\u003c\/p\u003e \u003cp\u003e6.5 Inorganic Nanocarriers 207\u003c\/p\u003e \u003cp\u003e6.6 Benefits of Bioactive-Based Nanoparticles for Occular Application 210\u003c\/p\u003e \u003cp\u003e6.7 Challenges and Future Considerations 211\u003c\/p\u003e \u003cp\u003e6.8 Conclusion 212\u003c\/p\u003e \u003cp\u003eAcknowledgment 212\u003c\/p\u003e \u003cp\u003eReferences 213\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Bioactive-Based Nanocarriers for Gastrointestinal System Disease 223\u003cbr\u003e \u003c\/b\u003e\u003ci\u003ePhool Chandra, Rashmi Pathak, Neetu Sachan, Ashok Kumar Gupta and Anurag Verma\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 224\u003c\/p\u003e \u003cp\u003e7.2 Types of Bioactive-Based Nanocarriers 231\u003c\/p\u003e \u003cp\u003e7.3 Design and Fabrication of Bioactive-Based Nanocarriers 236\u003c\/p\u003e \u003cp\u003e7.4 Bioactive Molecules for Targeting Gastrointestinal Diseases 238\u003c\/p\u003e \u003cp\u003e7.5 Preclinical Studies and Clinical Trials 242\u003c\/p\u003e \u003cp\u003e7.6 Therapeutic Applications of Bioactive-Based Nanocarriers 245\u003c\/p\u003e \u003cp\u003e7.7 Safety and Toxicity Considerations 250\u003c\/p\u003e \u003cp\u003e7.8 Challenges and Future Perspectives 253\u003c\/p\u003e \u003cp\u003e7.9 Conclusion 254\u003c\/p\u003e \u003cp\u003eReferences 255\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Bioactive-Based Nanocarriers for Cancer Treatment and Targeting 265\u003cbr\u003e \u003c\/b\u003e\u003ci\u003ePetra O. Nnamani, Ozioma B. Onokala and Oluwatoyin A. Odeku\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Overview of Current Global Epidemiology and Prevalence of Cancer 266\u003c\/p\u003e \u003cp\u003e8.2 Comparison and Contrast Between Bioactive‐Based Nanocarriers and Other Cancer Treatment 266\u003c\/p\u003e \u003cp\u003e8.3 Mechanism(s) for Cancer Treatment and Targeting Using Bioactive Compounds 270\u003c\/p\u003e \u003cp\u003e8.4 Bioactive-Based Nanocarriers for Treatment and Targeting of Different Categories of Cancer 277\u003c\/p\u003e \u003cp\u003e8.5 Limitations of Bioactive-Based Nanocarriers for Cancer Treatment and Targeting 285\u003c\/p\u003e \u003cp\u003e8.6 Future prospects 285\u003c\/p\u003e \u003cp\u003e8.7 Conclusion 286\u003c\/p\u003e \u003cp\u003eReferences 286\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Bioactive-Based Nanocarrier for the Management of Infectious Diseases 299\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eManisha Pandey, Pooja, Deepika Sharma, Sunita Nirban, Ashwani Arya, Suchitra Nishal, Manish Dhall, Neha Jain and Tarun Kumar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 300\u003c\/p\u003e \u003cp\u003e9.2 Factors Influencing Bioactive Nanocarriers 304\u003c\/p\u003e \u003cp\u003e9.3 Mechanism of Action of Bioactive Nanocarriers in Infection 307\u003c\/p\u003e \u003cp\u003e9.4 Recent Advancements in Bioactive-Based Nanocarrier for Infections 314\u003c\/p\u003e \u003cp\u003e9.5 Beneficial Aspects of Bioactive-Based Nanocarrier Over Conventional Treatment 323\u003c\/p\u003e \u003cp\u003e9.6 Conclusion and Future Prospects 329\u003c\/p\u003e \u003cp\u003eReferences 329\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Bioactive-Based Nanocarriers for Cosmeceuticals 339\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eBhavana Singh, Gautam Kumar, Vandana, Hema Arya, Deepika Joshi, Urvashi Saxena, Sumitra Singh and Rakesh K. Sindhu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 340\u003c\/p\u003e \u003cp\u003e10.2 Nanotechnology in Cosmeceuticals 342\u003c\/p\u003e \u003cp\u003e10.3 Bioactive Ingredients in Cosmeceuticals 346\u003c\/p\u003e \u003cp\u003e10.4 Nanocarriers for Bioactive Delivery 351\u003c\/p\u003e \u003cp\u003e10.5 Applications of Bioactive-Based Nanocarriers in Cosmeceuticals 354\u003c\/p\u003e \u003cp\u003e10.6 Challenges and Future Perspectives 361\u003c\/p\u003e \u003cp\u003eReferences 364\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Bioactive-Based Nanocarriers for CVD 369\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSwapnali Patil, Pranali Pangam and Poournima Sankpal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 370\u003c\/p\u003e \u003cp\u003e11.2 The Ongoing CVD Crisis 370\u003c\/p\u003e \u003cp\u003e11.3 Bioactive Compounds and Their Role in Cardiovascular Disease (CVD) Prevention and Treatment 374\u003c\/p\u003e \u003cp\u003e11.4 Role of Bioactive Compounds in CVD Prevention 374\u003c\/p\u003e \u003cp\u003e11.5 Bioactive-Based Nanocarriers for Enhanced Drug Delivery 377\u003c\/p\u003e \u003cp\u003e11.6 Challenges and Future Directions 380\u003c\/p\u003e \u003cp\u003e11.7 Conclusion 383\u003c\/p\u003e \u003cp\u003eReferences 384\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Bioactive-Based Nanocarriers for Diabetes 389\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDeepak Kumar, Ankit Kumar Singh, Adarsh Kumar, Harshwardhan Singh, Jagat Pal Yadav and Pradeep Kumar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAbbreviations 390\u003c\/p\u003e \u003cp\u003e12.1 Introduction 390\u003c\/p\u003e \u003cp\u003e12.2 Bioactive-Based Nanocarriers in Medicine and Healthcare Including Diabetes 394\u003c\/p\u003e \u003cp\u003e12.3 Significance of Material Selection in Bioactive-Based Nanocarriers 399\u003c\/p\u003e \u003cp\u003e12.4 Targeting Strategies for Diabetes Therapy 399\u003c\/p\u003e \u003cp\u003e12.5 Benefits of Targeted Drug Delivery in Diabetes 401\u003c\/p\u003e \u003cp\u003e12.6 Factors Affecting Drug Loading Efficiency and Stability in Encapsulation Systems 403\u003c\/p\u003e \u003cp\u003e12.7 Opportunities for Improving Nanocarrier Performance and Targeting Specificity 406\u003c\/p\u003e \u003cp\u003e12.8 Ethical and Regulatory Considerations 407\u003c\/p\u003e \u003cp\u003e12.9 Challenges and Future Perspectives 409\u003c\/p\u003e \u003cp\u003e12.10 Conclusion 410\u003c\/p\u003e \u003cp\u003eAcknowledgments 410\u003c\/p\u003e \u003cp\u003eReferences 411\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Bioactive-Based Nanocarriers in Management of CNS Diseases 417\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSatish Polshettiwar, Pankaj Khuspe, Amol Gholap, Prasad Aldar and Mangesh Godbole\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 418\u003c\/p\u003e \u003cp\u003e13.2 Principles of Bioactive-Based Nanocarriers 422\u003c\/p\u003e \u003cp\u003e13.3 Overcoming the Blood–Brain Barrier 428\u003c\/p\u003e \u003cp\u003e13.4 Nanocarriers of Hope: Revolutionizing Neurodegenerative Disease Management 435\u003c\/p\u003e \u003cp\u003e13.5 Applications in Neurodegenerative Diseases 436\u003c\/p\u003e \u003cp\u003e13.6 Bioactive-Based Nanocarriers for Brain Tumor Therapy 438\u003c\/p\u003e \u003cp\u003e13.7 Bioactive-Based Nanocarriers in Stroke Management 439\u003c\/p\u003e \u003cp\u003e13.8 Traumatic Brain Injury and Nanocarrier Interventions 440\u003c\/p\u003e \u003cp\u003e13.9 Imaging and Diagnostic Capabilities 441\u003c\/p\u003e \u003cp\u003e13.10 Current Preclinical and Clinical Advancements 442\u003c\/p\u003e \u003cp\u003e13.11 Future Prospects and Challenges 443\u003c\/p\u003e \u003cp\u003e13.12 Conclusion 444\u003c\/p\u003e \u003cp\u003eReferences 445\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Nanocarrier Applications for the Delivery of Bioactives for Topical Wound Healing 461\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eİmren Esentürk-Güzel, Merve Nur Özdemir, Evren Algın Yapar and Meryem Sedef Erdal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 462\u003c\/p\u003e \u003cp\u003e14.2 Physiology of Wound Healing 463\u003c\/p\u003e \u003cp\u003e14.3 Skin Drug Delivery for Wound-Healing Applications 465\u003c\/p\u003e \u003cp\u003e14.4 Research on Wound Healing Using Nanocarriers Loaded with Bioactive Materials 468\u003c\/p\u003e \u003cp\u003e14.5 Prospects and Challenges of Nanocarriers in Future Wound Healing 493\u003c\/p\u003e \u003cp\u003eReferences 494\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Bioactive-Based Nanocarriers for Targeting Antimicrobial Resistance 509\u003cbr\u003e \u003c\/b\u003e\u003ci\u003ePaka Sravan Kumar, Farmiza Begum, Chaman Bala, Bhavana Singh, Rakesh Kumar Sindhu and Gautam Kumar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 510\u003c\/p\u003e \u003cp\u003e15.2 Development of Antibiotic Resistance 510\u003c\/p\u003e \u003cp\u003e15.3 Mechanism of Antibiotic Resistance 511\u003c\/p\u003e \u003cp\u003e15.4 Current Treatment Approaches to Management Antibiotic Resistance and Challenges 514\u003c\/p\u003e \u003cp\u003e15.5 Phytochemicals in the Management of Antibiotic Resistance 517\u003c\/p\u003e \u003cp\u003e15.6 Phytochemical-Based Nanocarriers for the Management of Antibiotic Resistance 520\u003c\/p\u003e \u003cp\u003e15.7 Mechanism of Phytochemical-Based Nanocarriers in Combating Antibiotic Resistance 521\u003c\/p\u003e \u003cp\u003e15.8 Conclusion and Future Perspectives 522\u003c\/p\u003e \u003cp\u003eReferences 522\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Bioactive Phytochemical–Based Nanocarriers for Targeting Non-Alcoholic Fatty Liver Disease (NAFLD) 525\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGautam Kumar, Sara Fathima, Prasada Chowdari Gurram, Chaman Bala, Rakesh Kumar Sindhu and Farmiza Begum\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 526\u003c\/p\u003e \u003cp\u003e16.2 Etiology and Pathophysiology 526\u003c\/p\u003e \u003cp\u003e16.3 Current Treatment Options Available for NAFLD 528\u003c\/p\u003e \u003cp\u003e16.4 Bioactive-Based Nanocarriers: A Treatment Option for NAFLD as Smart Drug Carriers 541\u003c\/p\u003e \u003cp\u003e16.5 Toxicological Concerns of Nanocarriers for NAFLD Therapy 548\u003c\/p\u003e \u003cp\u003e16.6 Merits and Demerits of Bioactive-Based Nanocarriers for NAFLD Treatment 550\u003c\/p\u003e \u003cp\u003e16.7 Conclusion and Future Perspectives 551\u003c\/p\u003e \u003cp\u003eReferences 552\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Bioactive Peptide–Based Nanocarrier and Its Application 563\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSailee Chowdhury, Subhabrota Majumdar, Dipanjan Karati, Koyel Kar and Rana Mazumder\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 564\u003c\/p\u003e \u003cp\u003e17.2 Brief Attention on Peptides 564\u003c\/p\u003e \u003cp\u003e17.3 Bioactive Peptide as Nanocarriers 565\u003c\/p\u003e \u003cp\u003e17.4 Conclusion and Future Outlook 577\u003c\/p\u003e \u003cp\u003eReferences 578\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Bioactive-Based Nanocarriers for the Treatment of Lung Disorders 587\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eShayeri Chatterjee Ganguly, Sumon Giri and Moumita Kundu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Introduction 588\u003c\/p\u003e \u003cp\u003e18.2 Advantages and Challenges of Nanocarriers in Lung Disease Treatment 589\u003c\/p\u003e \u003cp\u003e18.3 Role of Bioactive Nanocarriers in Lung Disease Management 590\u003c\/p\u003e \u003cp\u003e18.4 Bioactive-Based Nanocarriers in Asthma Management 591\u003c\/p\u003e \u003cp\u003e18.5 Bioactive-Based Nanocarriers in COPD Treatment 595\u003c\/p\u003e \u003cp\u003e18.6 Pulmonary Fibrosis and Bioactive Nanocarrier Approaches 598\u003c\/p\u003e \u003cp\u003e18.7 Bioactive Nanocarriers for Cystic Fibrosis Treatment 600\u003c\/p\u003e \u003cp\u003e18.8 Tuberculosis Management with Bioactive-Based Nanocarriers 603\u003c\/p\u003e \u003cp\u003e18.9 Future Perspectives and Conclusion 605\u003c\/p\u003e \u003cp\u003eReferences 606\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Bioactive-Based Nanotherapeutics in Pain Management: A Revolutionary Approach 619\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSumon Giri, Zainab Irfan, Shaikh Ershadul Haque, Shayeri Chatterjee Ganguly and Stabak Das\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19.1 Introduction 619\u003c\/p\u003e \u003cp\u003e19.2 Pathophysiology of Pain 620\u003c\/p\u003e \u003cp\u003e19.3 Pain Biomarkers 622\u003c\/p\u003e \u003cp\u003e19.4 Treatment for Pain Management 627\u003c\/p\u003e \u003cp\u003e19.5 Significance of Bioactive Compound–Based Nanotherapeutics in Pain Therapy 629\u003c\/p\u003e \u003cp\u003e19.6 Nanotherapeutics: A New Strategy from the Bioactive Compounds for the Treatment of Pain 632\u003c\/p\u003e \u003cp\u003e19.7 Conclusion 647\u003c\/p\u003e \u003cp\u003eReferences 648\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Bioactive-Based Nanocarriers for Neonatal Drug Delivery System: Enhancing Efficacy and Safety in Neonatal Medicine 663\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eA. Mohamed Noufal, R. Sabitha and S. Akilandeswari\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20.1 Introduction 664\u003c\/p\u003e \u003cp\u003e20.2 Nanocarrier Design Considerations for Neonatal Use 665\u003c\/p\u003e \u003cp\u003e20.3 Bioactive Components in Nanocarrier Systems 667\u003c\/p\u003e \u003cp\u003e20.4 Enhancing Drug Encapsulation, Stability, and Sustained Release 670\u003c\/p\u003e \u003cp\u003e20.5 Minimizing Toxicity and Immunogenicity 672\u003c\/p\u003e \u003cp\u003e20.6 Exploiting Neonatal Physiology for Targeted Delivery 674\u003c\/p\u003e \u003cp\u003e20.7 Nanocarrier Surface Modification and Ligand Conjugation 675\u003c\/p\u003e \u003cp\u003e20.8 Improving Drug Bioavailability in Neonatal Populations 678\u003c\/p\u003e \u003cp\u003e20.9 Promising Applications of Bioactive-Based Nanocarriers in Neonatal Medicine 679\u003c\/p\u003e \u003cp\u003e20.10 Advancements and Future Perspectives 681\u003c\/p\u003e \u003cp\u003e20.11 Conclusion 681\u003c\/p\u003e \u003cp\u003eReferences 682\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Bioactive-Based Nanocarriers for the Treatments of Obesity: A Novel Approach 691\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eLoveleen Kaur, Baljinder Singh, Raghav Tandon, Reecha Madaan, Rakesh K. Sindhu and Sumitra Singh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21.1 Introduction 692\u003c\/p\u003e \u003cp\u003e21.2 Pathophysiology 693\u003c\/p\u003e \u003cp\u003e21.3 Management of Obesity 695\u003c\/p\u003e \u003cp\u003e21.4 Bioactive Compounds 699\u003c\/p\u003e \u003cp\u003e21.5 Nanotechnology 701\u003c\/p\u003e \u003cp\u003e21.6 Conclusion\/Future Perspectives 704\u003c\/p\u003e \u003cp\u003eReferences 705\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Regulatory Aspects of Bioactive-Based Nanocarriers 715\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eFarmiza Begum, Chaman Bala, Fathima Beegum, Sara Fathima, Rakesh Kumar Sindhu and Gautam Kumar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22.1 Introduction 716\u003c\/p\u003e \u003cp\u003e22.2 The Necessity of Regulating Nanomedicine 717\u003c\/p\u003e \u003cp\u003e22.3 Worldwide Strategies for the Regulation of Nanopharmaceuticals 717\u003c\/p\u003e \u003cp\u003e22.4 Conclusion 724\u003c\/p\u003e \u003cp\u003eReferences 725\u003c\/p\u003e \u003cp\u003eIndex 727\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Chemistry [\u003ca title=\"See our other books on Chemistry\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Chemistry%20%5BPN%5D%22\"\u003ePN\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Scrivener","offers":[{"title":"Brand New","offer_id":52433295573272,"sku":"9781394287314","price":236.19,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9781394287314.jpg?v=1784853172","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/bioactive-based-nanotherapeutics-hardback-9781394287314","provider":"Freshly Printed Books","version":"1.0","type":"link"}